EGFR and cancer: Abnormal deposition of extracellular matrix (ECM) components creates a stiff environment that is increasingly being recognized for its regulatory yet essential role in a majority of the “cancer hallmarks.”[6] ECM rigidity increases mechanosignaling associated with poor prognosis.[7] Seemingly, these cell–ECM interactions can activate EGFR in cancer cells although the precise molecular mechanisms remain unclear,[8] presenting a significant barrier toward developing effective targeted therapies for EGFR‐driven cancers.